相关实验视频
Updated: Mar 7, 2026

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
1.2K
吗啡因作为神经退行性疾病治疗的特权支架
Saranya Kattil Parmbil1, Sunil Kumar1, T M Rangarajan2
1Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus Kochi 682 041 India bijomathew@aims.amrita.edu bijovilaventgu@gmail.com.
RSC advances
|March 6, 2026
概括
吗波林衍生物显示出对中枢神经系统 (CNS) 药物开发的巨大潜力. 这些化合物有效抑制关键酶和调节神经递质通路,为神经精神疾病提供新的治疗途径.
科学领域:
- 药用化学 医学化学
- 神经药理学神经药理学
- 药物发现 药物发现 药物发现
背景情况:
- 吗波林是一种异环化合物,因其多种药理性质而闻名.
- 在治疗神经退行性和神经精神疾病方面,人们正在研究吗啡衍生物.
- 这些化合物作为酶抑制剂和神经递质调节剂.
研究的目的:
- 阐明吗在中枢神经系统药物开发中的治疗意义.
- 评估吗啡因在抑制单胺氧化酶和胆化酶中的作用.
- 为了评估吗啡衍生物对北上腺素和多巴胺通路的向.
主要方法:
- 对同行评审出版物的系统文献搜索.
- 评估morpholine基化合物的结构意义和药理潜力.
- 对酶抑制和途径调节数据的分析.
主要成果:
- 吗波林衍生物显示出有前途的疗效和选择性.
- 这些化合物在特定情况下可以超过传统药物.
- 形态素支架提供平衡的脂性-水性特征,并增强了血脑屏障的透性.
结论:
- 吗波林衍生物代表了中枢神经系统药物发现的有价值的支架.
- 进一步的研究应该集中在优化衍生品以提高选择性,疗效和安全性.
- 这些化合物有可能解决神经精神疾病中未满足的医疗需求.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
765
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
765

